218 related articles for article (PubMed ID: 32328671)
21. Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor.
Itoh K; Platsoucas CD; Balch CM
J Exp Med; 1988 Oct; 168(4):1419-41. PubMed ID: 3262710
[TBL] [Abstract][Full Text] [Related]
22. Immunosensitization of melanoma tumor cells to non-MHC Fas-mediated killing by MART-1-specific CTL cultures.
Frost PJ; Butterfield LH; Dissette VB; Economou JS; Bonavida B
J Immunol; 2001 Mar; 166(5):3564-73. PubMed ID: 11207317
[TBL] [Abstract][Full Text] [Related]
23. IL-12 stimulates CTLs to secrete exosomes capable of activating bystander CD8
Li L; Jay SM; Wang Y; Wu SW; Xiao Z
Sci Rep; 2017 Oct; 7(1):13365. PubMed ID: 29042682
[TBL] [Abstract][Full Text] [Related]
24. Antimelanoma activity of CTL generated from peripheral blood mononuclear cells after stimulation with autologous dendritic cells pulsed with melanoma gp100 peptide G209-2M is correlated to TCR avidity.
Yang S; Linette GP; Longerich S; Haluska FG
J Immunol; 2002 Jul; 169(1):531-9. PubMed ID: 12077285
[TBL] [Abstract][Full Text] [Related]
25. The exocytosis of lytic granules is impaired in Vti1b- or Vamp8-deficient CTL leading to a reduced cytotoxic activity following antigen-specific activation.
Dressel R; Elsner L; Novota P; Kanwar N; Fischer von Mollard G
J Immunol; 2010 Jul; 185(2):1005-14. PubMed ID: 20543108
[TBL] [Abstract][Full Text] [Related]
26. Melanoma Cells Control Antimelanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase.
Inozume T; Yaguchi T; Furuta J; Harada K; Kawakami Y; Shimada S
J Invest Dermatol; 2016 Jan; 136(1):255-63. PubMed ID: 26763445
[TBL] [Abstract][Full Text] [Related]
27. Clinical-Grade Human Multipotent Adult Progenitor Cells Block CD8+ Cytotoxic T Lymphocytes.
Plessers J; Dekimpe E; Van Woensel M; Roobrouck VD; Bullens DM; Pinxteren J; Verfaillie CM; Van Gool SW
Stem Cells Transl Med; 2016 Dec; 5(12):1607-1619. PubMed ID: 27465071
[TBL] [Abstract][Full Text] [Related]
28. CTL Attenuation Regulated by PS1 in Cancer-Associated Fibroblast.
Zhang H; Jiang R; Zhou J; Wang J; Xu Y; Zhang H; Gu Y; Fu F; Shen Y; Zhang G; Feng L; Zhang X; Chen Y; Shen F
Front Immunol; 2020; 11():999. PubMed ID: 32587587
[No Abstract] [Full Text] [Related]
29. Increase in activated CD8+ T lymphocytes expressing perforin and granzyme B correlates with disease activity in patients with systemic lupus erythematosus.
Blanco P; Pitard V; Viallard JF; Taupin JL; Pellegrin JL; Moreau JF
Arthritis Rheum; 2005 Jan; 52(1):201-11. PubMed ID: 15641052
[TBL] [Abstract][Full Text] [Related]
30. Transcriptomic features of tumour-infiltrating CD4
Parrot T; Oger R; Allard M; Desfrançois J; Raingeard de la Blétière D; Coutolleau A; Preisser L; Khammari A; Dréno B; Delneste Y; Guardiola P; Fradin D; Gervois N
Sci Rep; 2020 Apr; 10(1):5900. PubMed ID: 32246006
[TBL] [Abstract][Full Text] [Related]
31. Polyfunctional response by ImmTAC (IMCgp100) redirected CD8
Boudousquie C; Bossi G; Hurst JM; Rygiel KA; Jakobsen BK; Hassan NJ
Immunology; 2017 Nov; 152(3):425-438. PubMed ID: 28640942
[TBL] [Abstract][Full Text] [Related]
32. Modulation of CD8+ CTL effector function by fibroblasts derived from the immunoprivileged cornea.
Knickelbein JE; Divito S; Hendricks RL
Invest Ophthalmol Vis Sci; 2007 May; 48(5):2194-202. PubMed ID: 17460279
[TBL] [Abstract][Full Text] [Related]
33. Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma.
Mackensen A; Meidenbauer N; Vogl S; Laumer M; Berger J; Andreesen R
J Clin Oncol; 2006 Nov; 24(31):5060-9. PubMed ID: 17075125
[TBL] [Abstract][Full Text] [Related]
34. Adoptive T cell immunotherapy of human uveal melanoma targeting gp100.
Sutmuller RP; Schurmans LR; van Duivenvoorde LM; Tine JA; van Der Voort EI; Toes RE; Melief CJ; Jager MJ; Offringa R
J Immunol; 2000 Dec; 165(12):7308-15. PubMed ID: 11120866
[TBL] [Abstract][Full Text] [Related]
35. Cx43-Gap Junctions Accumulate at the Cytotoxic Immunological Synapse Enabling Cytotoxic T Lymphocyte Melanoma Cell Killing.
Hofmann F; Navarrete M; Álvarez J; Guerrero I; Gleisner MA; Tittarelli A; Salazar-Onfray F
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31547237
[TBL] [Abstract][Full Text] [Related]
36. Measuring melanoma-specific cytotoxic T lymphocytes elicited by dendritic cell vaccines with a tumor inhibition assay in vitro.
Paczesny S; Shi H; Saito H; Mannoni P; Fay J; Banchereau J; Palucka AK
J Immunother; 2005; 28(2):148-57. PubMed ID: 15725959
[TBL] [Abstract][Full Text] [Related]
37. Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs.
Wong RM; Scotland RR; Lau RL; Wang C; Korman AJ; Kast WM; Weber JS
Int Immunol; 2007 Oct; 19(10):1223-34. PubMed ID: 17898045
[TBL] [Abstract][Full Text] [Related]
38. Topical treatment of all-trans retinoic acid inhibits murine melanoma partly by promoting CD8
Yin W; Song Y; Liu Q; Wu Y; He R
Immunology; 2017 Oct; 152(2):287-297. PubMed ID: 28556970
[TBL] [Abstract][Full Text] [Related]
39. Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanoma.
Rimoldi D; Rubio-Godoy V; Dutoit V; Lienard D; Salvi S; Guillaume P; Speiser D; Stockert E; Spagnoli G; Servis C; Cerottini JC; Lejeune F; Romero P; Valmori D
J Immunol; 2000 Dec; 165(12):7253-61. PubMed ID: 11120859
[TBL] [Abstract][Full Text] [Related]
40. Identification of known and novel immunogenic T-cell epitopes from tumor antigens recognized by peripheral blood T cells from patients responding to IL-2-based treatment.
Scheibenbogen C; Sun Y; Keilholz U; Song M; Stevanovic S; Asemissen AM; Nagorsen D; Thiel E; Rammensee HG; Schadendorf D
Int J Cancer; 2002 Mar; 98(3):409-14. PubMed ID: 11920592
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
